Phase 2 Head and Neck Cancer Trial, Recruiting NCT04151082 Sponsor: M.D. Anderson Cancer Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT04151082
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adult survivors of oropharyngeal cancer (for the clinical trial) or head and neck cancer (for the registry) who currently show no signs of cancer.
  • People who finished radiation treatment at least 2 years ago, confirmed through scans and medical check-ups.
  • People who have developed nerve damage affecting the tongue and/or swallowing — a late side effect of radiation — where scans, physical examination, or biopsy have ruled out a structural or cancer-related cause.
  • People who are willing and able to return for a follow-up assessment after steroid treatment (clinical trial only).
  • People who are able to complete a symptom survey in one of the supported languages: English, simplified Chinese, Filipino, Greek, Japanese, Korean, Russian, Spanish, or Taiwanese.

Who may not be able to join:

  • People with diabetes that is not well controlled.
  • People with high blood pressure that is not well controlled (specifically, a top number above 160 or a bottom number above 90).
  • People with a known stomach or intestinal ulcer.
  • People with a history of psychosis (a condition involving a break from reality).
  • People who are pregnant.
  • People who have a narrowing or blockage in the throat or food pipe that has not been treated or has not responded to treatment.
  • People with a known history or diagnosis of bipolar disorder.
  • People who have had surgery near the nerve pathway under the tongue (clinical trial only) (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Katherine A Hutcheson, BA,MS,PHD, M.D. Anderson Cancer Center

Phone: 713-792-6513

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 October 2019
Est. completion
31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum tolerated dose; Change in MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) top 5 mean

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov